Switch theme
Sign up to access all valuation multiples
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
2015
81
LTM Revenue $2.7M
LTM EBITDA n/a
-$66.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Connect Biopharma has a last 12-month revenue of $2.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Connect Biopharma achieved revenue of n/a and an EBITDA of -$58.4M.
Connect Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Connect Biopharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $24.2M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$58.4M | n/a | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | NaN% | XXX | XXX | XXX |
| Net Profit | -$205M | -$116M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -478% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 13, 2025, Connect Biopharma's stock price is $1.
Connect Biopharma has current market cap of $43.4M, and EV of -$66.5M.
See Connect Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$66.5M | $43.4M | XXX | XXX | XXX | XXX | $-0.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 13, 2025, Connect Biopharma has market cap of $43.4M and EV of -$66.5M.
Connect Biopharma's trades at -3.4x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Connect Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Connect Biopharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$66.5M | XXX | XXX | XXX |
| EV/Revenue | -2.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | -3.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpConnect Biopharma's NTM/LTM revenue growth is -80%
Connect Biopharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Connect Biopharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Connect Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Connect Biopharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Connect Biopharma acquired XXX companies to date.
Last acquisition by Connect Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Connect Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Connect Biopharma founded? | Connect Biopharma was founded in 2015. |
| Where is Connect Biopharma headquartered? | Connect Biopharma is headquartered in United States of America. |
| How many employees does Connect Biopharma have? | As of today, Connect Biopharma has 81 employees. |
| Who is the CEO of Connect Biopharma? | Connect Biopharma's CEO is Dr. Zheng Wei, PhD. |
| Is Connect Biopharma publicy listed? | Yes, Connect Biopharma is a public company listed on NAS. |
| What is the stock symbol of Connect Biopharma? | Connect Biopharma trades under CNTB ticker. |
| When did Connect Biopharma go public? | Connect Biopharma went public in 2021. |
| Who are competitors of Connect Biopharma? | Similar companies to Connect Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Connect Biopharma? | Connect Biopharma's current market cap is $43.4M |
| What is the current revenue of Connect Biopharma? | Connect Biopharma's last 12-month revenue is $2.7M. |
| What is the current EV/Revenue multiple of Connect Biopharma? | Current revenue multiple of Connect Biopharma is -3.4x. |
| Is Connect Biopharma profitable? | Yes, Connect Biopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
